CMV reactivation in nonmyeloablative HSCT

Bone Marrow Transplantation

Volumn 27, Issue 7, 2001, Pages 775-

  Graber, C ^a   De Almeider, K N F ^a   Childs, R ^b   Barrett, A J ^b   Gill, V J ^c   Bennett, J E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN DETECTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LYMPHOCYTE DEPLETION; PNEUMONIA; POPULATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; RETINITIS; RETROSPECTIVE STUDY; RISK; SEROLOGY; T LYMPHOCYTE; TIME OF DEATH; VIREMIA; VIRUS REACTIVATION;

CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; VIRUS ACTIVATION;

EID: 17744398818     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702871     Document Type: Letter

References (2)

1. Workshop on CMV disease: Definitions, clinical severity scores, and new syndromes
2. Elevated serum cytokines are associated with cytomegalovirus infection and disease in hematopoietic stem cell transplant patients